CSL LTD SPON.ADR 2 (CSJA) - Net Assets
Based on the latest financial reports, CSL LTD SPON.ADR 2 (CSJA) has net assets worth €20.55 Billion EUR (≈ $24.02 Billion USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€38.45 Billion ≈ $44.95 Billion USD) and total liabilities (€17.90 Billion ≈ $20.93 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of CSL LTD SPON.ADR 2 for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €20.55 Billion |
| % of Total Assets | 53.44% |
| Annual Growth Rate | 13.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.02 |
CSL LTD SPON.ADR 2 - Net Assets Trend (2022–2025)
This chart illustrates how CSL LTD SPON.ADR 2's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see CSL LTD SPON.ADR 2 (CSJA) total market value.
Annual Net Assets for CSL LTD SPON.ADR 2 (2022–2025)
The table below shows the annual net assets of CSL LTD SPON.ADR 2 from 2022 to 2025. Read CSL LTD SPON.ADR 2 debt and liabilities for a breakdown of total debt and financial obligations.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €21.41 Billion ≈ $25.03 Billion |
+10.34% |
| 2024-06-30 | €19.40 Billion ≈ $22.68 Billion |
+8.84% |
| 2023-06-30 | €17.83 Billion ≈ $20.84 Billion |
+22.28% |
| 2022-06-30 | €14.58 Billion ≈ $17.04 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CSL LTD SPON.ADR 2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 31.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €17.74 Billion | 91.77% |
| Other Components | €1.59 Billion | 8.23% |
| Total Equity | €19.34 Billion | 100.00% |
CSL LTD SPON.ADR 2 Competitors by Market Cap
The table below lists competitors of CSL LTD SPON.ADR 2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lumentum Holdings Inc
NASDAQ:LITE
|
$40.18 Billion |
|
Consolidated Edison Inc
NYSE:ED
|
$40.18 Billion |
|
Kia Corp
KO:000270
|
$40.19 Billion |
|
Public Service Enterprise Group Inc
NYSE:PEG
|
$40.27 Billion |
|
JD.com Inc Adr
NASDAQ:JD
|
$40.04 Billion |
|
Aselsan Elektronik Sanayi ve Ticaret AS
IS:ASELS
|
$40.04 Billion |
|
Banco BTG Pactual S.A.
SA:BPAC11
|
$39.92 Billion |
|
Prudential plc
MX:PUKN
|
$39.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSL LTD SPON.ADR 2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,363,000,000 to 19,335,000,000, a change of 1,972,000,000 (11.4%).
- Net income of 3,002,000,000 contributed positively to equity growth.
- Dividend payments of 1,434,000,000 reduced retained earnings.
- New share issuances of 17,000,000 increased equity.
- Other factors increased equity by 387,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.00 Billion | +15.53% |
| Dividends Paid | €1.43 Billion | -7.42% |
| Share Issuances | €17.00 Million | +0.09% |
| Other Changes | €387.00 Million | +2.0% |
| Total Change | €- | 11.36% |
Book Value vs Market Value Analysis
This analysis compares CSL LTD SPON.ADR 2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.60x to 0.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €30.26 | €18.20 | x |
| 2023-06-30 | €32.73 | €18.20 | x |
| 2024-06-30 | €35.93 | €18.20 | x |
| 2025-06-30 | €39.93 | €18.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSL LTD SPON.ADR 2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.46%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.04x
- Recent ROE (15.53%) is above the historical average (15.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 15.47% | 21.49% | 0.37x | 1.94x | €796.95 Million |
| 2023 | 13.90% | 16.65% | 0.36x | 2.30x | €615.40 Million |
| 2024 | 15.22% | 17.99% | 0.39x | 2.19x | €905.70 Million |
| 2025 | 15.53% | 19.46% | 0.39x | 2.04x | €1.07 Billion |
Industry Comparison
This section compares CSL LTD SPON.ADR 2's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,825,485,895
- Average return on equity (ROE) among peers: -60.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSL LTD SPON.ADR 2 (CSJA) | €20.55 Billion | 15.47% | 0.87x | $40.06 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $350.23 Million | -54.44% | 0.83x | $817.53 Million |
| PreveCeutical Medical Inc (18H) | $-296.06K | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $1.97 Billion | -15.31% | 0.08x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $2.19 Million | -197.55% | 0.15x | $3.31 Million |
About CSL LTD SPON.ADR 2
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more